cancer of the cervix cervical cancer
Conditions
Interventions
In the second part of the study, patient will be vaccinated after completion of
the 2nd cycle of chemotherapy. Further chemotherapeutic treatment will continue
according to the oncology protocol.
Sponsors
Leids Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Patients should be at least 18 years of age; - Patients should be able and willing to provide informed consent; - Patients with a diagnosis of histologically confirmed cervical cancer that is clinically and/or radiologically proven advanced, recurrent or metastatic for whom no curative treatment (surgery or radiotherapy) options are available; - Patients scheduled for standard chemotherapy with Carboplatin / Paclitaxel;
Exclusion criteria
Exclusion criteria: For all patients (first and second cohort) the following exclusion criteria apply: - Any condition that in the opinion of the treating physician(s) is likely to jeopardise the well-being of health status of the patient; - Another active malignancy - Positive test result for HIV
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • The time related immune response during and after standard chemotherapy in patients with advanced, recurrent or metastatic cervical cancer; • The time and treatment related response to an HPV16 Synthetic Long Peptide (SLP) immunization in cervical cancer patients, after completion of the standard chemotherapy. | — |
Countries
Netherlands
Outcome results
None listed